Figure S15 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Q: What type of study is this?

This is a Experimental Study study.

Zahra Davoudi; Thomas S. Dexheimer; Nathan P. Coussens; Thomas Silvers; Raymond G. Fox; Samantha B. Kemp; Punita Juneja; Joel Morris; Melinda G. Hollingshead; Naoko Takebe; James H. Doroshow; Beverly A. Teicher

doi:10.1158/2767-9764.30304705

October 8, 2025

Figure S15 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combination therapy shows significant activity against multicell-type tumor spheroids derived from various cancers, enhancing treatment options.
Employing batoprotafib and venetoclax resulted in notable synergy, improving efficacy in targeting oncogenic kras variants across different cancer types.
Analysis focuses on the combinatorial effects of targeted agents, specifically batoprotafib and venetoclax, to enhance cancer treatment strategies.
These findings suggest that targeted combinations could optimize therapeutic outcomes in patient-derived tumor models, indicating new avenues for research.

Implication

Combination activity of ras pathway inhibitors with targeted agents shows potential in multicell-type tumor spheroids, highlighting effective treatment strategies for oncogenic kras variants.

Abstract

Figure S15. Combination activity of batoprotafib with venetoclax in multicell-type tumor spheroids.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3b9c https://doi.org/10.1158/2767-9764.30304705

View Full Paper

Ask AI

Bookmark

Share

Figure S15 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S15 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading